Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Stelara was first approved for psoriasis 10 years ago, and follow-up indications in psoriatic arthritis and Crohn’s disease have kept the drug growing at a healthy pace to reach more than $5 ...

Otulfi (ustekinumab-aauz) demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Stelara® in patients with moderate to severe plaque psoriasis.

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Meanwhile, Johnson & Johnson's Stelara is becoming an increasingly popular choice, generating sales around $2.3 billion last year in psoriasis and Crohn’s disease. But it has a different ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...